Researchers recommend ‘caution’ when using the chemotherapy busulfan in patients with Gilbert’s syndrome
Oct. 27, 2016
| By Susan Keown / Fred Hutch News Service
As many as one of every 10 people has Gilbert's syndrome, which is typically benign and has even been linked to long life. But new research suggests that busulfan, a bone marrow transplant drug, is extra risky in people with the condition.
Clinical Research Division study shows 41 percent drop in post-transplant deaths compared to mid-1990s
Nov. 29, 2010
| By Dean Forbes
Refinements over the last 10 years in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at the Fred Hutchinson Cancer Research Center.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.